Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | CCR1 | P32246 | 1/20 | 0.31 |
| ▸ | CCR8 | P51685 | 1/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.30 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.30 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.30 |
| ▸ | CD44 | P16070 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1091757 | 0.73 | CYP1A2 (0.35) | CYP2A6CYP1A2ALDH1A1TSHRTDP1 | |
| SCHEMBL1092191 | 0.72 | GABRA1 (0.40) | GABRA1GABRB2 | |
| SCHEMBL67570 | 0.64 | CYP2A6 (0.35) | CYP2A6CYP1A2ALDH1A1CA1CA2 | |
| SCHEMBL28461475 | 0.64 | CYP1A2 (0.35) | CYP2A6CYP1A2ALDH1A1CA1CA2 | |
| SCHEMBL1105075 | 0.63 | — | — | |
| SCHEMBL25894 | 0.60 | — | — | |
| SCHEMBL3819593 | 0.60 | CYP2A6 (0.41) | CYP2A6CYP1A2ALDH1A1CA1CA2 | |
| Water SCHEMBL5434332 | 0.59 | CYP2A6 (0.39) | CYP2A6CYP1A2ALDH1A1CA1CA2 | |
| SCHEMBL20960205 | 0.57 | ACHE (0.71) | CYP2A6CYP1A2ALDH1A1CA1CA2 | |
| SCHEMBL1686908 | 0.57 | ALDH1A1 (0.48) | CYP2A6CYP1A2ALDH1A1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2809668-B1 | 4-(BENZOIMIDAZOL-2-YL)-THIAZOLE COMPOUNDS AND RELATED AZA DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2017-04-12 | — | — | EP | claimed |
| US-9266876-B2 | 4-(benzoimidazol-2-yl)-thiazole compounds and related aza derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-02-23 | — | — | US | claimed |
| US-20140371204-A1 | 4-(Benzoimidazol-2-yl)-thiazole Compounds and Related Aza Derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2014-12-18 | — | — | US | claimed |
| EP-2809668-A1 | 4-(BENZOIMIDAZOL-2-YL)-THIAZOLE COMPOUNDS AND RELATED AZA DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2014-12-10 | — | — | EP | claimed |
| WO-2013114332-A1 | 4-(BENZOIMIDAZOL-2-YL)-THIAZOLE COMPOUNDS AND RELATED AZA DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2013-08-08 | — | — | WO | claimed |
| EP-1441719-B1 | N-SUBSTITUTED PYRROLIDIN DERIVATIVES AS DIPEPTIDYL PEPTIDASE IV INHIBITORS | HOFFMANN LA ROCHE (CH) | 2011-03-30 | — | — | EP | claimed |
| US-7803819-B2 | DPP IV inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2010-09-28 | — | — | US | claimed |
| US-20070259925-A1 | DPP IV INHIBITORS | BOEHRINGER MARKUS | 2007-11-08 | — | — | US | claimed |
| US-20050096348-A1 | DPP IV inhibitors | BOEHRINGER MARKUS (CH) | 2005-05-05 | — | — | US | claimed |
| US-20030130281-A1 | DPP IV inhibitors | HOFFMAN-LA ROCHE INC. | 2003-07-10 | — | — | US | claimed |
| EP-2809668-B1 | 4-(BENZOIMIDAZOL-2-YL)-THIAZOLE COMPOUNDS AND RELATED AZA DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2017-04-12 | — | — | EP | disclosed |
| US-9266876-B2 | 4-(benzoimidazol-2-yl)-thiazole compounds and related aza derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-02-23 | — | — | US | disclosed |
| US-20140371204-A1 | 4-(Benzoimidazol-2-yl)-thiazole Compounds and Related Aza Derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2014-12-18 | — | — | US | disclosed |
| EP-2809668-A1 | 4-(BENZOIMIDAZOL-2-YL)-THIAZOLE COMPOUNDS AND RELATED AZA DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2014-12-10 | — | — | EP | disclosed |
| WO-2013114332-A1 | 4-(BENZOIMIDAZOL-2-YL)-THIAZOLE COMPOUNDS AND RELATED AZA DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2013-08-08 | — | — | WO | disclosed |
| US-7314884-B2 | non-insulin dependent diabetes mellitus, and impaired glucose tolerance; dipeptidyl peptidase IV (DPP-IV) inhibitors eg (2S)-1-{[(1S)-2-(5-cyano-2-methyl-indol-1-yl)-1-methyl-ethylamino]-acetyl}-pyrrolidine-2-carbonitrile | HOFFMANN-LA ROCHE INC. (US) | 2008-01-01 | — | — | US | disclosed |
| US-20070259925-A1 | DPP IV INHIBITORS | BOEHRINGER MARKUS | 2007-11-08 | — | — | US | disclosed |
| US-20050096348-A1 | DPP IV inhibitors | BOEHRINGER MARKUS (CH) | 2005-05-05 | — | — | US | disclosed |
| US-6861440-B2 | DPP IV inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2005-03-01 | — | — | US | disclosed |
| US-20030130281-A1 | DPP IV inhibitors | HOFFMAN-LA ROCHE INC. | 2003-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371204-A1 | 4-(Benzoimidazol-2-yl)-thiazole Compounds and Related Aza Derivatives | CXCR3, CXCR1, CXCR2 | CYP2A6 2684/4885CYP1A2 1322/4885ALDH1A1 1249/4885 |
| US-20070259925-A1 | DPP IV INHIBITORS | DPP4, DPP3, DPP7 | CYP2A6 382/4885CYP1A2 555/4885ALDH1A1 233/4885 |
| US-20030130281-A1 | DPP IV inhibitors | DPP4, DPP3, DPP7 | CYP2A6 724/4885CYP1A2 655/4885ALDH1A1 133/4885 |
| US-20050096348-A1 | DPP IV inhibitors | DPP4, DPP3, DPP7 | CYP2A6 382/4885CYP1A2 555/4885ALDH1A1 233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.